Invitae (NYSE:NVTA) Now Covered by StockNews.com

Investment analysts at StockNews.com began coverage on shares of Invitae (NYSE:NVTA) in a note issued to investors on Thursday. The firm set a “hold” rating on the medical research company’s stock.

Invitae Stock Performance

Shares of Invitae stock opened at $0.00 on Thursday. Invitae has a 12-month low of $0.02 and a 12-month high of $0.02. The company has a market cap of $453,917.00, a P/E ratio of 0.00 and a beta of 1.59. The company’s fifty day simple moving average is $0.01 and its two-hundred day simple moving average is $0.30.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC bought a new position in Invitae in the third quarter worth $29,000. Strs Ohio grew its position in shares of Invitae by 46.9% in the 3rd quarter. Strs Ohio now owns 569,800 shares of the medical research company’s stock worth $344,000 after buying an additional 181,800 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Invitae by 4.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,652,650 shares of the medical research company’s stock valued at $1,000,000 after acquiring an additional 64,228 shares during the period. Barclays PLC lifted its position in Invitae by 698.2% during the 3rd quarter. Barclays PLC now owns 905,531 shares of the medical research company’s stock valued at $548,000 after acquiring an additional 792,091 shares during the period. Finally, Janney Montgomery Scott LLC boosted its stake in Invitae by 404.6% during the third quarter. Janney Montgomery Scott LLC now owns 63,105 shares of the medical research company’s stock worth $38,000 after acquiring an additional 50,600 shares in the last quarter. Institutional investors own 61.28% of the company’s stock.

About Invitae

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.